Yahoo奇摩 網頁搜尋

  1. BNT輝瑞疫苗 相關
  1. Pfizer–BioNTech COVID-19 vaccine - Wikipedia › wiki › Pfizer–BioNTech_COVID-19_vaccine

    The Pfizer–BioNTech COVID-19 vaccine ( INN: tozinameran ), sold under the brand name Comirnaty, is an mRNA -based COVID-19 vaccine developed by the German biotechnology company BioNTech and for it's development collaborated with American ...

  2. Pfizer - Wikipedia › wiki › Pfizer

    Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart, two cousins who had immigrated to the United States from Ludwigsburg, Germany, the year before. The business produced chemical compounds, and was headquartered on Bartlett ...

    • 78,500, of whom 29,400 are in the United States (2020)
    • 1849; 172 years ago in New York City
    • $41.908 billion (2020)
    • 235 East 42nd Street, New York City, U.S.
  3. BioNTech - Wikipedia › wiki › BioNTech
    • History
    • Corporate Affairs
    • Business Activities
    • See Also
    • External Links


    BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, and Christoph Huber, with a seed investment of €150 million. The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy. Andreas and Thomas Strüngmann, Michael Motschmann, and Helmut Jeggle were cofounders. In 2009, the acquisition of EUFETS and JPT Peptide Technologies took place. Katalin Karikó, whose work on mRNA whilst working at the Universit...


    Between 2014 and 2018, many research results on mRNA mechanisms were published by BioNTech. Collaborations and commercialization programs were concluded with various companies and scientific institutions starting in 2015. During this period, BioNTech filed several patent applications and developed a multi-layered strategy to protect its intellectual property in the various technology platforms and their application in the treatment of cancer and other serious diseases.[citation needed] In Aug...

    Nasdaq IPO (2019) to COVID-19

    Since 10 October 2019, BioNTech, with its newly founded North American headquarters in Cambridge, Massachusetts, has been publicly traded as American Depository Shares (ADS) on the NASDAQ Global Select Market under the ticker symbol, BNTX. BioNTech was able to generate total gross proceeds of 150 million dollars from the IPO. In 2021, BioNTech announced it would open its Asia headquarters in Singapore, and also open a vaccine manufacturing plant there, with support from the Singapore Economic...


    BioNTech's founding place and global headquarters is Mainz, Germany, where the COVID-19 vaccine was created. The company runs multiple sites in the city.Further research locations are in San Diego and Cambridge, Massachusetts, the latter of which also serves as the North American headquarters. Additionally the company owns GMP-certified production facilities in Idar-Oberstein, Martinsried, Neuried, and Berlin. In November 2020, the company acquired facilities from Novartis in Marburg to ramp...


    In December 2019, BioNTech received a €50 million loan, to finance the development of its patient-specific immunotherapies for the treatment of cancer and other serious diseases, from the European Investment Bank (EIB) as part of the European Commission Investment Plan for Europe. The EIB then signed a €100 million loan in June 2020, after an accelerated approval (two months for a process that usually takes more than a year). This financing helped BioNTech's vaccine trials and manufacturing....

    Vaccine development

    "Project Lightspeed", the project to develop a novel mRNA technology for a COVID-19 vaccine, began in mid-January 2020 just days after the SARS-Cov-2 genetic sequence was first made public. The company is partnered on this project with Pfizer and Fosun. The production of the vaccine was followed by clinical trials, the success of which was a prerequisite for the commencement of marketing. On 9 November 2020, BioNTech and Pfizer announced that 43,500 people in 6 countries had received a test v...

    Vaccine distribution timeline

    In July 2020, BioNTech and pharmaceutical corporation Pfizer signed contracts to supply 120 million doses for Japan, 100 million doses for the United States at $19.50, and 40 million doses for the United Kingdom, if proven effective, safe, and licensed. On 5 August 2020, Canada pre-ordered 20 million doses of the vaccine. In September 2020, Germany privately ordered 30 million doses, outside the collective EU purchasing scheme. On 5 November 2020, Australia pre-ordered 10 million doses. On 9...

  4. COVID-19 vaccine - Wikipedia › wiki › Covid-19_vaccine

    A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).Prior to the COVID‑19 pandemic, an established ...

  5. 其他人也搜尋了
  1. BNT輝瑞疫苗 相關